🔴 Breaking

Biotech firm secures £36m to advance ulcerative colitis treatment • Salience Labs secures 125 million dollars funding • Olympic medallist secures £4.6m for preventative health startup • UK Deploys AI to Shield Critical Infrastructure from Cyber Threats • Sava raises 36 million in funding round • Manchester Angels makes 22 investments in tech firms • Manchester single mum builds EdTech platform to support teachers • Oxford Metrics buys Move AI assets cheaply • FoundersNybble Sponsors FUEL Manchester to Boost Startups • North Defence Appoints Katie Mallinson as Public Affairs Director Biotech firm secures £36m to advance ulcerative colitis treatment • Salience Labs secures 125 million dollars funding • Olympic medallist secures £4.6m for preventative health startup • UK Deploys AI to Shield Critical Infrastructure from Cyber Threats • Sava raises 36 million in funding round • Manchester Angels makes 22 investments in tech firms • Manchester single mum builds EdTech platform to support teachers • Oxford Metrics buys Move AI assets cheaply • FoundersNybble Sponsors FUEL Manchester to Boost Startups • North Defence Appoints Katie Mallinson as Public Affairs Director

Tag

therapy

Biotech firm secures £36m to advance ulcerative colitis treatment

Biotech firm secures £36m to advance ulcerative colitis treatment

A UK biotech firm raises £36m in Series C funding to advance its microbiome-based ulcerative colitis treatment, MB310, backed by Tencent and British Business Ba

Yolla Septiani · -280 minutes ago